Multivariate competing risk regression analysis for relapse at 3 years after alloHCT
| Multivariable analysis with variables at diagnosis . | HR . | 95% confidence interval . | P value . |
|---|---|---|---|
| CK at diagnosis (vs not) | 2.56 | 0.98-6.68 | .055 |
| ICC-defined TP53mut MN (vs does not meet) | 2.02 | 0.85-4.77 | .11 |
| Non-DBD TP53mut only (vs ≥1 DBD mutation) | 2.09 | 0.8-5.48 | .13 |
| DNMT3A comutation (vs not) | 2.47 | 1.15-5.32 | .021 |
| Multivariable analysis with variables at diagnosis . | HR . | 95% confidence interval . | P value . |
|---|---|---|---|
| CK at diagnosis (vs not) | 2.56 | 0.98-6.68 | .055 |
| ICC-defined TP53mut MN (vs does not meet) | 2.02 | 0.85-4.77 | .11 |
| Non-DBD TP53mut only (vs ≥1 DBD mutation) | 2.09 | 0.8-5.48 | .13 |
| DNMT3A comutation (vs not) | 2.47 | 1.15-5.32 | .021 |
| Multivariable analysis with variables at pre-alloHCT . | HR . | 95% confidence interval . | P value . |
|---|---|---|---|
| Cytogenetic response | |||
| CK at diagnosis, but not pre-alloHCT (vs no CK) | 2.1 | 0.87-5.05 | .1 |
| CK pre-alloHCT (vs no CK) | 2.33 | 0.93-5.86 | .071 |
| Melphalan-based conditioning (vs no melphalan) | 0.56 | 0.33-0.95 | .032 |
| PTCy-based GVHD prophylaxis (vs not) | 1.49 | 0.88-2.52 | .14 |
| Pre-alloHCT BM blasts ≥5% (vs <5% blasts) | 1.71 | 0.73-4.02 | .22 |
| Multivariable analysis with variables at pre-alloHCT . | HR . | 95% confidence interval . | P value . |
|---|---|---|---|
| Cytogenetic response | |||
| CK at diagnosis, but not pre-alloHCT (vs no CK) | 2.1 | 0.87-5.05 | .1 |
| CK pre-alloHCT (vs no CK) | 2.33 | 0.93-5.86 | .071 |
| Melphalan-based conditioning (vs no melphalan) | 0.56 | 0.33-0.95 | .032 |
| PTCy-based GVHD prophylaxis (vs not) | 1.49 | 0.88-2.52 | .14 |
| Pre-alloHCT BM blasts ≥5% (vs <5% blasts) | 1.71 | 0.73-4.02 | .22 |
Boldface values indicate statistically significant at P < 0.05.